GH Research PLC
GHRSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. At a $1.24B market cap, GH Research PLC ranks as a small-cap company within healthcare. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Market Cap
$1.24B
Beta
1.32
P/E (TTM)
—
P/E (Fwd)
-9.77
EPS (TTM)
$-0.99
EPS (Fwd)
$-1.85
ROE
-18.8%
ROA
-13.0%
Cash
$362.6M
Total Debt
$360,000
Free CF
-$36.5M
52W Change
26.2%
Annual Financials
Cash vs Debt
Where GHRS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GHRS finished 21.41% below its 150-day moving average ($23.26) and 14.42% below its 200-day moving average ($21.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GHRS overbought or oversold?
At the October 20, 2026 close, GHRS's RSI(14) was 13.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $362.6M in cash and $360K in debt, GHRS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$36.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -18.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GH Research PLC's trajectory.